

## Curriculum Vitae

### Carlo Rivolta, PhD

Head of the Unit of Medical Genetics  
Department of Computational Biology  
University of Lausanne  
Rue du Bugnon 27  
CH-1011 Lausanne, Switzerland

Phone +41-21-692-5451  
Fax +41-21-692-5455  
Email [carlo.rivolta@unil.ch](mailto:carlo.rivolta@unil.ch)  
Web [www.unil.ch/dbc](http://www.unil.ch/dbc)



**Google Scholar ID:** [11SiG4AAAAJ](https://scholar.google.com/citations?user=11SiG4AAAAJ)

**ORCID ID:** [0000-0002-0733-9950](https://orcid.org/0000-0002-0733-9950)

#### **Summary of qualifications:**

Medical geneticist, with expertise in the fields of genomics, transcriptomics, next-generation sequencing, and in general in large-scale experimental approaches in relationship to ophthalmic disorders. Strong background and skills in bioinformatics, statistics, and computer programming, in addition to competences in molecular biology and classic human genetics.

#### **Research interests:**

Molecular genetics of retinal dystrophies and hereditary diseases with elevated allelic heterogeneity. Computational approaches to genomics of monogenic to complex conditions, with specific interest in quasi-Mendelian conditions, modifier genes, and oligogenic inheritance.

#### **Education:**

- 1989-1994: Master of Science (Molecular Biology) *cum laude*. University of Pavia, Italy
- 1997: Twelve-month postgraduate course in bioinformatics at the Swiss Federal Institute of Technology Lausanne (EPFL), Switzerland
- 1994-1999: Ph.D. in Science (Molecular Genetics) *cum laude*. University of Lausanne, Switzerland

#### **Postdoctoral training:**

- 1999-2003: Postdoctoral fellowship in the group of Prof. Thaddeus P. Dryja at Harvard Medical School, Massachusetts Eye and Ear Infirmary (MEEI/MGH), Boston, USA

#### **Academic career:**

- 2003-2004: Instructor (Junior Faculty) of the Medical School, Harvard
- 2004-2008: Junior Group Leader (Maître Assistant), Department of Medical Genetics, University of Lausanne
- 2008-present: Tenured Group Leader (Maître d'Enseignement et de Recherche I), University of Lausanne
- 2012: Privat Dozent (University of Lausanne)
- 2017-present: Full Professor, Chair of Medical Genetics, Department of Genetics and Genome Biology, University of Leicester, UK

#### **Formal Teaching (University of Lausanne):**

- 2006-2007: Classes of "Medical Genetics", to medical students, 4<sup>th</sup> year
- 2009-2010: "Ocular Genetics", Ph.D. program in Neurosciences
- 2010-2011: Course of Genomic Sequencing, Master MLS program
- 2007-present: "Human Molecular Genetics", Master MLS program
- 2010-present: "Human Molecular Genetics", Ph.D. (all UNIL's Ph.D. programs)
- 2012-present: "Write a review", Master MLS program
- 2015-present: Course "Restore vision: from bench to bedside" (Genetics of retinal dystrophies module), to all Ph.D. programs
- 2015-present: "Genes and vision", to medical students, 4<sup>th</sup> year

### ***Other duties (Lausanne):***

- Ph.D. fellowship, FBM, member of the board (2006-present)
- Member of the "Conseil de l'Ecole Doctorale", FBM (2009-2014)
- Member of the "Bâtiment Bugnon 27" committee (2006-2010)
- Member of the "Commission de la recherche", FBM (2009-2010)
- UNIL representative for the SNF Div. 3 at SNF Research Day (2006)
- Departmental head for biosafety (2005-present)
- Elected member of the Medicine and Biology Faculty Council (2013-present)

### ***Other duties (Switzerland):***

- Principal investigator for the Genetic Research Days (federal program for the education of the general public) (2007-present)
- Member of the Forum Genforschung (FoGeFo), Swiss Academy of Sciences (SCNAT), Bern (2015-2016)
- Member of the Working Group "Personalized Health" (FoGeFo, SCNAT), Bern (2016-present)

### ***Other duties (Leicester):***

- Member of the Leicester Precision Medicine Institute (LPMI) (2017-present)
- Member of the Genomics England Clinical Interpretation Partnership (GeCIP, hearing and sight) (2018-present)

### ***Editorial and reviewing activities:***

- Member of the Editorial Board of: Journal of Human Genetics (Nature PG), Vision (MDPI, Basel), Scientific Reports (Nature PG)
- Reviewer for (Journals): Nature Genetics, American Journal of Human Genetics, Journal of Medical Genetics, BMC Medical Genetics, Human Molecular Genetics, Human Mutation, Journal of Clinical Investigations, Nature Biotechnology, Genetics in Medicine, European Journal of Medical Genetics, Nature Neuroscience, etc.
- Reviewer for (Funding Bodies): The Wellcome Trust, Swiss National Science Foundation, Swiss League Against Cancer, Netherlands Organization for Health Research and Development, Agence Nationale de la Recherche (F), Czech Science Foundation, etc.

### ***Memberships:***

The Association for Research in Vision and Ophthalmology (ARVO), Swiss Society of Ophthalmology (SSO), Swiss Society of Medical Genetics (SSMG), International Society for Eye Research (ISER), the American Society of Human Genetics (ASHG), the European Retinal Disease Consortium (ERDC), National Center for Competences in Research (NCCR) RNA and disease

### ***Mentoring:***

Approximately 40 people so far, including M.Sc. students, M.D. students, Ph.D. students, and postdocs

### ***Current lab:***

Ten people: 5 Ph.D. students, 3 postdocs, 1 intern, 1 lab manager

### ***Publications:***


81 peer-reviewed articles, of which 41 during the last 5 years; please see the annexed document

### ***Competitive extramural funding:***

Approximately \$ 8,800,000 as a group leader; please see the annexed document

### ***Citations:***

9,932 (4,138 during the last 5 years), as of March 2018.



## Extramural Funding

### **Swiss National Science Foundation (SNF) (2017 – 2021)**

Only applicant of the project “Non-Mendelian inheritance in retinal degenerations”  
*Div.3 Research Grant, Independent Basic Research. \$ 860,000*

### **Novartis Stiftung für medizinisch-biologische Forschung (2018)**

Co-applicant of the project “The Domino-Drosophila ensemble for the functional validation of new ID genes”  
*Research Grant. \$ 64,000*

### **Fond’action contre le cancer (2017 – 2019)**

Leading applicant of the project “New therapies for metastatic uveal melanoma through whole genome sequencing, epigenetic and pharmacological studies”  
*Research Grant. \$ 500,000*

### **Swiss National Science Foundation (SNF) (2014 – 2017)**

Only applicant of the project “New genomic concepts in hereditary retinal degeneration”  
*Div.3 Research Grant, Independent Basic Research. \$ 400,000*

### **Fond’action contre le cancer (2014 – 2017)**

Leading applicant of the project “Genomic bases of the uveal melanoma”  
*Research Grant. \$ 150,000*

### **Swiss National Science Foundation (SNF) - Sinergia (2013 – 2016)**

Leading applicant of the project “A synergistic approach for the analysis and gene replacement therapy for FAM161A deficiencies”  
*Cooperative research grant (3 groups). \$ 1,320,000*

### **Swiss National Science Foundation (SNF) (2011 – 2014)**

Only applicant of the project “Molecular genetics of retinitis pigmentosa: identification and functional analysis of new disease genes”  
*Div.3 Research Grant, Independent Basic Research. \$ 540,000*

### **The Gebert Rüt Foundation (2009-2012)**

Leading applicant of the project “Gene hunting for recessive hereditary peripheral neuropathies by recent and highly-parallel technologies”  
*Rare Diseases– New Technologies grant (3 groups). \$ 480,000*

### **European Union (2007-2011)**

Coordinator of the Swiss group (20 groups in total, 3 Swiss sub-groups) of the project “Hypergenes”  
*Framework Programme 7. \$ 3,520,000 for the Swiss group (~\$ 3,300,000 for my group)*

### **Swiss National Science Foundation (SNF) (2008 – 2011)**

Only applicant of the project “Molecular genetics of PRPF splicing factors in retinitis pigmentosa”  
*Div.3 Research Grant, Independent Basic Research. \$ 320,000*

### **Synopsis Foundation (2008-2010)**

Co-applicant (out of 4 investigators) of the project “Elucidation of the pathogenic effects of non-coding repeat expansions in neurodegenerative disorders: FXTAS, DM2, SCA8-10-12, HD2.”  
*Synopsis Research Grant. \$ 214,000*

### **Swiss Multiple Sclerosis society (2008)**

Co-applicant (out of 7 investigators) of the project “Genetic analysis in a consanguineous family from Valais with a possibly monogenic form of multiple sclerosis”  
*Swiss multiple sclerosis society grant. \$ 55,000*

### **University of Lausanne Medical School (2006)**

Co-applicant (out of 14 investigators) of the project “CardioGene”  
*“Cardiomet” Research Grant. \$ 99,000*

### **Swiss National Science Foundation (SNF) (2005 – 2008)**

Leading applicant of the project “The splicing factor PRPF31 in human hereditary disease”  
*Div.3 Research Grant, Independent Basic Research. \$ 216,000*

## Publications

1. Fregni G, Quinodoz M, Möller E, Vuille J, Galland S, Fusco C, Martin P, Letovanec I, Provero P, **Rivolta C**, Riggi N, Stamenkovic I. (2018). Reciprocal modulation of mesenchymal stem cells and tumor cells promotes lung cancer metastasis. ***EBioMedicine*** (in press). Impact Factor: to be disclosed in June 2018.
2. Khateb S, Kowalewski B, Bedoni N, Damme M, Pollack N, Saada A, Obolensky A, Ben-Yosef T, Gross M, Dierks T\*, Banin E\*, **Rivolta C\***, Sharon D\*. (2018). A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans. ***Genet Med***. (in press). Impact Factor: 8.23. \*co-senior authors. Impact Factor: 8.23.
3. Quinodoz M, Royer-Bertrand B, Cisarova K, Di Gioia SA, Superti-Furga A, **Rivolta C**. (2017). DOMINO: using machine-learning to predict genes associated with dominant disorders. ***Am J Hum Genet***. 101:623-629. Impact Factor: 10.79
4. Volpi S, Yamazaki Y, Brauer PM, van Rooijen E, Hayashida A, Slavotinek A, Sun Kuehn H, Di Rocco M, **Rivolta C**, Bortolomai I, Du L, Felgentreff K, Ott de Bruin L, Hayashida K, Freedman G, Marcovecchio GE, Capuder K, Rath P, Luche N, Hagedorn EJ, Buoncompagni A, Royer-Bertrand B, Giliani S, Poliani PL, Imberti L, Dobbs K, Poulain FE, Martini A, Manis J, Linhardt RJ, Bosticardo M, Rosenzweig SD, Lee H, Puck JM, Zúñiga-Pflücker JC, Zon L, Park PW, Superti-Furga A, Notarangelo LD. (2017). *EXTL3* mutations cause skeletal dysplasia, immune deficiency, and developmental delay. ***J Exp Med***. 214:623-637. Impact Factor: 11.24
5. Coppieters F, Ascari G, Dannhausen K, Nikopoulos K, Peelman F, Karlstetter M, Xu M, Brachet C, Meunier I, Tsilimbaris MK, Tsika C, Blazaki SV, Vergult S, Farinelli P, Van Laethem T, Bauwens M, De Bruyne M, Chen R, Langmann T, Sui R, Meire F, **Rivolta C**, Hamel CP, Leroy BP, De Baere E. (2016). Isolated and Syndromic Retinal Dystrophy Caused by Biallelic Mutations in RCBTB1, a Gene Implicated in Ubiquitination. ***Am J Hum Genet***. 99:470-80. Impact Factor: 10.79
6. Royer-Bertrand B, Torsello M, Rimoldi D, El Zaoui I, Pescini-Gobert R, Raynaud F, Cisarova K, Zografos L, Schalenbourg A, Speiser D, Nicolas M, Vallat L, Klein R, Leyvraz S, Ciriello G, Riggi N, Moulin AP, **Rivolta C**. (2016). Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing. ***Am J Hum Genet***. 99:1190-8. Impact Factor: 10.79
7. Bedoni N, Haer-Wigman L, Vaclavik V, Tran V, Farinelli P, Balzano S, Royer-Bertrand B, El-Asrag M, Bonny O, Ikonomidis C, Litzistorf Y, Nikopoulos K, Yioti GG, Stefanidou MI, McKibbin M, Booth AP, Ellingford JM, Black GC, Toomes C, Inglehearn CF, Hoyng CB, Bax N, Klaver CCW, Thiadens AA, Murisier F, Schorderet DF, Ali M, Cremers FPM, Andreasson S, Munier FL, **Rivolta C**. (2016). Mutations in the polyglutamylase gene *TLL5*, expressed in photoreceptor cells and spermatozoa, are associated with cone-rod degeneration and reduced male fertility. ***Hum Mol Genet***. 25:4546-4555. Impact Factor: 5.98
8. Nikopoulos K, Farinelli P, Giangreco B, Tsika C, Royer-Bertrand B, Mbefo MK, Kjellstrom U, El Zaoui I, Di Gioia SA, Balzano S, Cisarova K, Messina A, Decembrini S, Plainis S, Mplazaki S, Khan MI, Michael S, Boldt K, Ueffing M, Moulin AP, Cremers FPM, Roepman R, Arsenijevic Y, Tsilimbaris MK, Andreasson S, **Rivolta C**. (2016). Mutations in *CEP78* cause cone-rod dystrophy and hearing loss associated with primary cilia defects. ***Am J Hum Genet***. 99:770-6. Impact Factor: 10.79
9. Kiper POS, Saito H, Gori F, Unger S, Hesse E, Yamana K, Kiviranta R, Solban N, Liu J, Brommage R, Boduroglu K, Bonafé L, Campos-Xavier B, Dikoglu E, Eastell R, Gossiel F, Harshman K, Nishimura G, Girisha KM, Stevenson BJ, Takita H, **Rivolta C**, Superti-Furga A\*, Baron R\* (2016). Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's Disease. ***N Engl J Med***. 374:2553-62. Impact Factor: 59.55. \*shared contribution
10. van Karnebeek CD, Bonafe L, Wen XY, Tarailo-Graovac M, Balzano S, Royer-Bertrand B, Ashikov A, Garavelli L, Mammi I, Turolla L, Breen C, Donnai D, Cormier V, Heron D, Nishimura G, Uchikawa S, Campos-

Xavier B, Rossi A, Hennet T, Brand-Arzamendi K, Rozmus J, Harshman K, Stevenson BJ, Girardi E, Superti-Furga G, Dewan T, Collingridge A, Halparin J, Ross CJ, Van Allen MI, Rossi A, Engelke UF, Kluijtmans LA, van der Heeft E, Renkema H, de Brouwer A, Huijben K, Zijlstra F, Heisse T, Boltje T, Wasserman WW, **Rivolta C**, Unger S, Lefeber DJ, Wevers RA and Superti-Furga A. (2016). NANS-mediated synthesis of sialic acid is required for brain and skeletal development. *Nat Genet*. 48:777-84. Impact Factor: 29.35

11. Sanchez-Alcudia R, Garcia-Hoyos M, Lopez-Martinez MA, Sanchez-Bolivar N, Zurita O, Gimenez A, Villaverde C, Rodrigues-Jacy da Silva L, Corton M, Perez-Carro R, Torriano S, Kalatzis V, **Rivolta C**, Avila-Fernandez A, Lorda I, Trujillo-Tiebas MJ, Garcia-Sandoval B, Lopez-Molina MI, Blanco-Kelly F, Riveiro-Alvarez R, Ayuso C. (2016). A Comprehensive Analysis of Choroideremia: From Genetic Characterization to Clinical Practice. *PLoS One*. 11: e0151943. Impact Factor: 3.23

12. Bonafé L, Kariminejad A, Li J, Royer-Bertrand B, Garcia V, Mahdavi S, Bozorgmehr B, Lachman RL, Mittaz-Crettol L, Campos-Xavier B, Nampoothiri S, Unger S, **Rivolta C**, Levade T, Superti-Furga A. (2016). Peripheral osteolysis in adults linked to ASAH1 (acid ceramidase) mutations: A new presentation of Farber disease. *Arthritis Rheumatol*. 68:2323-7. Impact Factor: 7.76

13. Sharon D, Kimchi A, **Rivolta C**. (2016). OR2W3 sequence variants are unlikely to cause inherited retinal diseases. *Ophthalmic Genet*. 18:1-3. Impact Factor: 1.45

14. Rose AM, Shah AZ, Venturini G, Krishna A, Chakravarti A, **Rivolta C**, Bhattacharya SS. (2016). Transcriptional regulation of PRPF31 gene expression by MSR1 repeat elements causes incomplete penetrance in retinitis pigmentosa. *Sci Rep*. 6:19450 Impact Factor: 5.58

15. Nikopoulos K, Butt GU, Farinelli P, Mudassar M, Domènech-Estévez E, Samara C, Kausar M, Masroor I, Chrast R, **Rivolta C\***, Siddiqi S\*. (2016). A large multiexonic genomic deletion within the ALMS1 gene causes Alström syndrome in a consanguineous Pakistani family. *Clin Genet* 89: 510-511. (\*equal contribution). Impact Factor: 3.89

16. **Rivolta C**, Royer-Bertrand B, Rimoldi D, Schalenbourg A, Zografos L, Leyvraz S, Moulin A. (2015). UV light signature in conjunctival melanoma; not only skin should be protected from solar radiation. *J Hum Genet*. 61:361-2. Impact Factor: 2.46

17. Royer-Bertrand B, Castillo-Taucher S, Moreno-Salinas R, Cho TJ, Chae JH, Choi M, Kim OH, Dikoglu E, Campos-Xavier B, Girardi E, Superti-Furga G, Bonafé L, **Rivolta C**, Unger S, Superti-Furga A. (2015). Mutations in the heat-shock protein A9 (HSPA9) gene cause the EVEN-PLUS syndrome of congenital malformations and skeletal dysplasia. *Sci Rep* 5:17154. Impact Factor: 5.58

18. Winkler TW, Justice AE, Graff M, Barata L,... **Rivolta C** ... , Borecki IB, Kutalik Z, Loos RJ. (2015). The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. *PLoS Genet* 10:e1005378. Impact Factor: 8.51

19. Nikopoulos K, Avila-Fernandez A, Corton M, Lopez-Molina MI, Perez-Carro R, Bontadelli L, Di Gioia SA, Zurita O, Garcia-Sandoval B, **Rivolta C\***, Ayuso C\*. (2015). Identification of two novel mutations in CDHR1 in consanguineous Spanish families with autosomal recessive retinal dystrophy. *Sci Rep* 5:13902. Impact Factor: 5.58

20. Safka Brozkova D, Deconinck T, Beth Griffin L, Ferbert A, Haberlova J, Mazanec R, Lassuthova P, Roth C, Pilunthanakul T, Rautenstrauss B, Janecke AR, Zavadakova P, Chrast R, **Rivolta C**, Zuchner S, Antonellis A, Beg AA, De Jonghe P, Senderek J, Seeman P, Baets J. (2015). Loss of function mutations in HARS cause a spectrum of inherited peripheral neuropathies. *Brain*. 138: 2161-2172. Impact Factor: 9.19

21. Garcia Segarra N, Ballhausen D, Crawford H, Perreau M, Campos-Xavier B, van Spaendonck-Zwarts K, Vermeer C, Russo M, Zambelli PY, Stevenson B, Royer-Bertrand B, **Rivolta C**, Candotti F, Unger S, Munier FL, Superti-Furga A, Bonafé L (2015). NBAS mutations cause a multisystem disorder involving bone, connective tissue, liver, immune system, and retina. *Am J Med Genet A* 167:2902-12. Impact Factor: 2.05

22. Di Gioia SA, Bedoni N, von Scheven-Gête A, Vanoni F, Superti-Furga A, Hofer M, **Rivolta C**. (2015). Analysis of the genetic basis of periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome. *Sci. Rep* 5:10200. Impact Factor: 5.58

23. Saqib MA, Nikopoulos K, Ullah E, Sher Khan F, Iqbal J, Bibi R, Jarral A, Sajid S, Nishiguchi KM, Venturini G, Ansar M, **Rivolta C. (2015)**. Homozygosity mapping reveals novel and known mutations in Pakistani families with inherited retinal dystrophies. ***Sci. Rep*** 5:9965. Impact Factor: 5.58
24. Di Gioia SA, Farinelli P, Letteboer SJ, Arsenijevic Y, Sharon D, Roepman R and **Rivolta C. (2015)**. Interactome analysis reveals that FAM161A, deficient in recessive retinitis pigmentosa, is a component of the Golgi-centrosomal network. ***Hum Mol Genet*** 15: 3359-3371. Impact Factor: 6.39
25. Bertelli C, Aeby S, Chassot B, Clulow J, Hilfiker O, Rappo S, Ritzmann S, Schumacher P, Terrettaz C, Benaglio P, Falquet L, Farinelli L, Gharib WH, Goesmann A, Harshman K, Linke B, Miyazaki R, **Rivolta C**, Robinson-Rechavi M, van der Meer JR, Greub G. **(2015)**. Sequencing and characterizing the genome of *Estrella lausannensis* as an undergraduate project: training students and biological insights. ***Front Microbiol*** 6:101. Impact Factor: 4.00
26. Zhao M, Andrieu-Soler C, Kowalczyk L, Paz Cortés M, Berdugo M, Dernigoghossian M, Halili F, Jeanny JC, Goldenberg B, Savoldelli M, El Sanharawi M, Naud MC, van Ijcken W, Pescini-Gobert R, Martinet D, Maass A, Wijnholds J, Crisanti P, **Rivolta C** and Behar-Cohen F. **(2015)**. A new CRB1 rat mutation links Müller glial cells to retinal telangiectasia. ***J Neurosci*** 35: 6093-6106. Impact Factor: 6.75
27. Benaglio P, San Jose PF, Avila-Fernandez A, Ascari G, Harper S, Manes G, Ayuso C, Hamel C, Berson EL and **Rivolta C. (2014)**. Mutational screening of splicing factor genes in cases with autosomal dominant retinitis pigmentosa. ***Mol Vis*** 20: 843-851. Impact Factor: 2.24
28. Hoggart CJ, Venturini G, Mangino M, ... **Rivolta C**, Loos RJ and Kutalik Z. **(2014)**. Novel approach identifies SNPs in SLC2A10 and KCNK9 with evidence for parent-of-origin effect on body mass index. ***PLoS Genet*** 10: e1004508. Impact Factor: 8.51
29. Miyazaki R, Bertelli C, Benaglio P, Canton J, De Coi N, Gharib WH, Gjoksi B, Goesmann A, Greub G, Harshman K, Linke B, Mikulic J, Mueller L, Nicolas D, Robinson-Rechavi M, **Rivolta C**, Roggo C, Roy S, Sentchilo V, Siebenthal AV, Falquet L and van der Meer JR. **(2014)**. Comparative genome analysis of *Pseudomonas knackmussii* B13, the first bacterium known to degrade chloroaromatic compounds. ***Environ Microbiol***. 17: 91-104. Impact Factor: 6.24
30. Nishiguchi KM, Avila-Fernandez A, van Huet RA, Corton M, Perez-Carro R, Martin-Garrido E, Lopez-Molina MI, Blanco-Kelly F, Hoefsloot LH, van Zelst-Stams WA, Garcia-Ruiz PJ, Del Val J, Di Gioia SA, Klevering BJ, van de Warrenburg BP, Vazquez C, Cremers FP, Garcia-Sandoval B, Hoyng CB, Collin RW, **Rivolta C\*** and Ayuso C\*. **(2014)**. Exome sequencing extends the phenotypic spectrum for ABHD12 mutations: from syndromic to nonsyndromic retinal degeneration. ***Ophthalmology*** 121: 1620-1627. Impact Factor: 5.56
31. Rahmioglu N, Macgregor S, Drong AW, Hedman AK, Harris HR, Randall JC, Prokopenko I, Nyholt DR, Morris AP, Montgomery GW, [Rivolta C as a group author] Missmer SA, Lindgren CM and Zondervan KT. **(2014)**. Genome-wide enrichment analysis between endometriosis and obesity-related traits reveals novel susceptibility loci. ***Hum Mol Genet*** 24: 1185-1199. Impact Factor: 7.54
32. Venturini G, Koskiniemi-Kuendig H, Harper S, Berson EL and **Rivolta C. (2014)**. Two specific mutations are prevalent causes of recessive retinitis pigmentosa in North American patients of Jewish ancestry. ***Genet Med*** 17: 285-290. Impact Factor: 6.43
33. Winkler TW, Day FR, Croteau-Chonka DC, Wood AR, Locke AE, Magi R, Ferreira T, Fall T, Graff M, Justice AE, Luan J, Gustafsson S, [Rivolta C as a group author] Randall JC, Vedantam S, Workalemahu T, Kilpelainen TO, Scherag A, Esko T, Kutalik Z, Heid IM and Loos RJ. **(2014)**. Quality control and conduct of genome-wide association meta-analyses. ***Nat Protoc*** 9: 1192-1212. Impact Factor: 7.78
34. Venturini G, Di Gioia SA, Harper S, Weigel-DiFranco C, **Rivolta C\*<sup>†</sup>** and Berson EL **(2014)\***. Molecular genetics of FAM161A in North American patients with early-onset retinitis pigmentosa. ***PLoS ONE*** 9: e94479 (\*equal contribution, <sup>†</sup>correspondence). Impact Factor: 3.73
35. Rose AM, Shah AZ, Venturini G, **Rivolta C**, Rose GE, Bhattacharya SS **(2014)**. Dominant PRPF31 mutations are hypostatic to a recessive CNOT3 polymorphism in retinitis pigmentosa: a novel phenomenon of "linked trans-acting epistasis". ***Ann Hum Genet***. 78:62-71. Impact Factor: 2.21
36. Nishiguchi KM, Tearle RG, Liu YP, Oh EC, Miyake N, Benaglio P, Harper S, Koskiniemi-Kuendig H,

Venturini G, Sharon D, Koenekoop RK, Nakamura M, Kondo M, Ueno S, Yasuma TR, Beckmann JS, Ikegawa S, Matsumoto N, Terasaki H, Berson EL, Katsanis N and **Rivolta C. (2013)**. Whole genome sequencing in patients with retinitis pigmentosa reveals pathogenic DNA structural changes and *NEK2* as a new disease gene. *Proc Natl Acad Sci U S A*. 110:16139-16144. Impact Factor: 9.73

37. Azzedine H, Zavadakova P, Plante-Bordeneuve V, Vaz Pato M, Pinto N, Bartesaghi L, Zenker J, Poirot O, Bernard-Marissal N, Arnaud Gouttenoire E, Cartoni R, Title A, Venturini G, Medard JJ, Makowski E, Schols L, Claeys KG, Stendel C, Roos A, Weis J, Dubourg O, Leal Loureiro J, Stevanin G, Said G, Amato A, Baraban J, Leguern E, Senderek J, **Rivolta C\*** and Chrast R.\* (2013). PLEKHG5 deficiency leads to an intermediate form of autosomal-recessive Charcot-Marie-Tooth disease. *Hum Mol Genet* 22:4224-4232. (\*equal contribution) Impact Factor: 7.54

38. Salvi E, Kuznetsova T, Thijs L, Lupoli S, Stolarz-Skrzypek K, D'Avila F, Tikhonoff V, De Astis S, Barcella M, Seidlerova J, Benaglio P, Malyutina S, Frau F, Velayutham D, Benfante R, Zagato L, Title A, Braga D, Marek D, Kawecka-Jaszcz K, Casiglia E, Filipovsky J, Nikitin Y, **Rivolta C**, Manunta P, Beckmann JS, Barlassina C, Cusi D and Staessen JA. (2013). Target sequencing, cell experiments, and a population study establish endothelial nitric oxide synthase (eNOS) gene as hypertension susceptibility gene. *Hypertension* 62: 844-852. Impact Factor: 6.87

39. Corton M, Nishiguchi KM, Avila-Fernandez A, Nikopoulos K, Riveiro-Alvarez R, Tatu SD, Ayuso C and **Rivolta C. (2013)**. Exome sequencing of index patients with retinal dystrophies as a tool for molecular diagnosis. *PLoS One* 8: e65574. Impact Factor: 3.73

40. Randall JC, Winkler TW, Kutalik Z, ... **Rivolta C**, ... *et al.* (2013). Sex-stratified Genome-wide Association Studies Including 270,000 Individuals Show Sexual Dimorphism in Genetic Loci for Anthropometric Traits. *PLoS Genet* 9: e1003500. Impact Factor: 8.51

41. Venturini G, Rose AM, Shah AZ, Bhattacharya SS and **Rivolta C. (2012)**. *CNOT3* is a modifier of *PRPF31* mutations in retinitis pigmentosa with incomplete penetrance. *PLoS Genet* 8: e1003040. Impact Factor: 8.51

42. Di Gioia SA, Letteboer SJ, Kostic C, Bandah-Rozenfeld D, Hetterschijt L, Sharon D, Arsenijevic Y, Roepman R and **Rivolta C. (2012)**. FAM161A, associated with retinitis pigmentosa, is a component of the cilia-basal body complex and interacts with proteins involved in ciliopathies. *Hum Mol Genet* 21:5174-5184. Impact Factor: 7.54

43. Avila-Fernandez A, Corton M, Nishiguchi KM, Muñoz-Sanz N, Benavides-Mori B, Blanco-Kelly F, Riveiro-Alvarez R, Garcia-Sandoval B, **Rivolta C** and Ayuso C. (2012). Identification of a *RP1* prevalent founder mutation and related phenotype in Spanish early-onset autosomal recessive retinitis patients. *Ophthalmology* 119:2616-2621. Impact Factor: 5.56

44. Nishiguchi KM and **Rivolta C (2012)**. Genes associated with retinitis pigmentosa and allied diseases are frequently mutated in the general population. *PLoS ONE* e41902. Impact Factor: 3.73

45. Venturini G, Moulin AP, Deprez M, Uffer S, Bottani A, Zografos L and **Rivolta C (2012)**. Clinico-pathological and molecular analysis of a choroidal pigmented schwannoma in the context of a PTEN hamartoma tumor syndrome. *Ophthalmology* 119:857-864. Impact Factor: 5.56

46. Salvi E, Kutalik Z, Glorioso N, Benaglio P ... **Rivolta C**, Munroe PB, Barlassina C, Staessen JA, Beckmann JS, Cusi D (2012). Genomewide Association Study Using a High-Density Single Nucleotide Polymorphism Array and Case-Control Design Identifies a Novel Essential Hypertension Susceptibility Locus in the Promoter Region of Endothelial NO Synthase. *Hypertension* 59:248-255. Impact Factor: 6.87

47. Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, Holm H, Sanna S, Kavousi M, et al. [Rivolta C as a group author] (2011). Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. *Nat Genet*. 43:1131-1138. Impact Factor: 35.20

48. Benaglio P, McGee TL, Capelli LP, Harper S, Berson EL and **Rivolta C (2011)**. Next generation sequencing of pooled samples reveals new *SNRNP200* mutations associated with retinitis pigmentosa. *Hum Mutat* 32:2246-2258. Impact Factor: 5.21

49. Tanackovic G, Ransijn A, Ayuso C, Harper S, Berson EL and **Rivolta C (2011)**. A missense mutation

in *PRPF6* causes impairment of pre-mRNA splicing and autosomal dominant retinitis pigmentosa. *Am J Hum Genet.* 88:643-649. Impact Factor: 11.20

50. Tanackovic G, Ransijn A, Thibault P, Abou Elela S, Klinck R, Berson EL, Chabot B and **Rivolta C (2011)**. *PRPF* mutations are associated with generalized defects in spliceosome formation and pre-mRNA splicing in patients with retinitis pigmentosa. *Hum Mol Genet* 20:2116-21130. Impact Factor: 7.54

51. Valsesia A, Rimoldi D, Martinet D, Ibberson M, Benaglio P, Gaillard M, Pidoux M, Rapin B, **Rivolta C**, Xenarios I, Simpson AJG, Antonarakis SE, Beckmann JS, Jongeneel CV, Iseli C, Stevenson BJ (2011). Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma. *PLoS ONE* 6:e18369. Impact Factor: 3.73

52. Lango Allen H, Estrada K, ... **Rivolta C** ... Frayling, TM and Hirschhorn JN (2010). Hundreds of variants clustered in genomic loci and biological pathways affect human height. *Nature.* 467:832-838. Impact Factor: 38.59

53. Benaglio P and **Rivolta C (2010)**. Ultra high throughput sequencing in human DNA variation detection: a comparative study on the *NDUFA3-PRPF31* region. *PLoS ONE.* 5: e13071. Impact Factor: 3.73

54. Langmann T, Di Gioia SA, Rau I, Stöhr H, Maksimovic NS, Corbo JC, Renner AB, Zrenner E, Kumaramanickavel G, Karlstetter M, Arsenijevic Y, Weber BH, Gal A and **Rivolta C (2010)**. Nonsense mutations in *FAM161A* cause RP28-associated recessive retinitis pigmentosa. *Am J Hum Genet.* 87: 376-381. Impact Factor: 11.20

55. Rio Frio T, Panek S, Iseli C, Di Gioia SA, Kumar A, Gal A and **Rivolta C (2009)**. Ultra high throughput sequencing excludes *MDH1* as candidate gene for RP28-linked retinitis pigmentosa. *Mol Vis.* 15: 2627-2633. Impact Factor: 2.20

56. Rio Frio T, McGee TL, Wade NM, Iseli C, Beckmann JS, Berson EL and **Rivolta C (2009)**. A single-base substitution within an intronic repetitive element causes dominant retinitis pigmentosa with reduced penetrance. *Hum Mutat.* 30: 1340-1347. Impact Factor: 5.21

57. Buttica C, Werge T, Beckmann JS, Cuenod M, Do KQ and **Rivolta C (2009)**. Mutation screening of the glutamate cysteine ligase modifier (*GCLM*) gene in patients with schizophrenia. *Psychiatr Genet.* 19: 201-208. Impact Factor: 2.36

58. Tanackovic G and **Rivolta C (2009)**. *PRPF31* alternative splicing and expression in human retina. *Ophthalmic Genet.* 30: 76-83. Impact Factor: 1.07

59. Fukada T\*, Civic N\*, Furuichi T\*, Shimoda S, Mishima K, Higashiyama H, Idaira Y, Asada Y, Kitamura H, Yamasaki S, Hojo S, Nakayama M, Ohara O, Koseki H, Dos Santos HG, Bonafe L, Ha-Vinh R, Zankl A, Unger S, Kraenzlin ME, Beckmann JS, Saito I\*, **Rivolta C\***, Ikegawa S\*, Superti-Furga A\* and Hirano T\*(2008). The zinc transporter *SLC39A13/ZIP13* is required for connective tissue development; its involvement in BMP/TGF-beta signaling pathways. *PLoS ONE.* 3: e3642. (\*equal contribution). Impact Factor: 3.73

60. Rio Frio T, Civic N, Ransijn A, Beckmann JS and **Rivolta C (2008)**. Two trans-acting eQTLs modulate the penetrance of *PRPF31* mutations. *Hum Mol Genet.* 17: 3154-3165. Impact Factor: 7.54

61. Rio Frio T, Wade NM, Ransijn A, Berson EL, Beckmann JS and **Rivolta C (2008)**. Premature termination codons in *PRPF31* cause retinitis pigmentosa via haploinsufficiency due to nonsense-mediated mRNA decay. *J Clin Invest.* 118: 1519-1531. Impact Factor: 12.81

62. **Rivolta C**#, Berson EL and Dryja TP (2006). Mutation screening of the peropsin gene, a retinal pigment epithelium specific rhodopsin homolog, in patients with retinitis pigmentosa and allied diseases. *Mol Vis.* 12: 1511-1515. (#corresponding author). Impact Factor: 2.20

63. **Rivolta C**, McGee TL, Rio Frio T, Jensen RV, Berson EL and Dryja TP (2006). Variation in retinitis pigmentosa-11 (*PRPF31* or *RP11*) gene expression between symptomatic and asymptomatic patients with dominant *RP11* mutations. *Hum Mutat.* 27: 644-653. Impact Factor: 5.21

64. Seyedahmadi BJ, **Rivolta C**, Keene JA, Berson EL and Dryja TP (2004). Comprehensive screening of the *USH2A* gene in Usher syndrome type II and non-syndromic recessive retinitis pigmentosa. *Exp Eye*



**Res.** 79: 167-173. Impact Factor: 3.02

65. Kobayashi K, Ehrlich SD, Albertini A ... **Rivolta C**, ... *et al.* (2003). Essential *Bacillus subtilis* genes. *Proc Natl Acad Sci U S A*. 100: 4678-4683. Impact Factor: 9.73

66. **Rivolta C**, Ayyagari R, Sieving PA, Berson EL and Dryja TP (2003). Evaluation of the *ELOVL4* gene in patients with autosomal recessive retinitis pigmentosa and Leber congenital amaurosis. *Mol Vis*. 9: 49-51. Impact Factor: 2.20

67. **Rivolta C**, Berson EL and Dryja TP (2002). Paternal uniparental heterodisomy with partial isodisomy of chromosome 1 in a patient with retinitis pigmentosa without hearing loss and a missense mutation in the Usher syndrome type II gene *USH2A*. *Arch Ophthalmol*. 120: 1566-1571. Impact Factor: 3.83

68. Wang X, Xu S, **Rivolta C**, Li LY, Peng GH, Swain PK, Sung CH, Swaroop A, Berson EL, Dryja TP and Chen S (2002). Barrier to autointegration factor interacts with the cone-rod homeobox and represses its transactivation function. *J Biol Chem*. 277: 43288-43300. Impact Factor: 4.65

69. **Rivolta C**, Sharon D, DeAngelis MM and Dryja TP (2002). Retinitis pigmentosa and allied diseases: numerous diseases, genes, and inheritance patterns. *Hum Mol Genet*. 11: 1219-1227. Impact Factor: 7.54

70. **Rivolta C**, Peck NE, Fulton AB, Fishman GA, Berson EL and Dryja TP (2001). Novel frameshift mutations in *CRX* associated with Leber congenital amaurosis. *Hum Mutat*. 18: 550-551. Impact Factor: 5.21

71. **Rivolta C**, Sweklo EA, Berson EL and Dryja TP (2000). Missense mutation in the *USH2A* gene: association with recessive retinitis pigmentosa without hearing loss. *Am J Hum Genet*. 66: 1975-1978. Impact Factor: 11.20

72. Bengtsson J, **Rivolta C**, Hederstedt L and Karamata D (1999). *Bacillus subtilis* contains two small c-type cytochromes with homologous heme domains but different types of membrane anchors. *J Biol Chem*. 274: 26179-26184. Impact Factor: 4.65

73. **Rivolta C** and Pagni M (1999). Genetic and physical maps of the *Bacillus subtilis* chromosome. *Genetics*. 151: 1239-1244. Impact Factor: 4.39

74. Bengtsson J, Tjalsma H, **Rivolta C** and Hederstedt L (1999). Subunit II of *Bacillus subtilis* cytochrome c oxidase is a lipoprotein. *J Bacteriol*. 181: 685-688. Impact Factor: 3.82

75. Robinson C, **Rivolta C**, Karamata D and Moir A (1998). The product of the *yvoC* (*gerF*) gene of *Bacillus subtilis* is required for spore germination. *Microbiology*. 144: 3105-3109. Impact Factor: 2.85

76. **Rivolta C**, Soldo B, Lazarevic V, Joris B, Mauel C and Karamata D (1998). A 35.7 kb DNA fragment from the *Bacillus subtilis* chromosome containing a putative 12.3 kb operon involved in hexuronate catabolism and a perfectly symmetrical hypothetical catabolite-responsive element. *Microbiology*. 144: 877-884. Impact Factor: 2.85

77. Reizer J\*, Hoischen C\*, Titgemeyer F\*, **Rivolta C\***, Rabus R\*, Stulke J\*, Karamata D, Saier MH, Jr. and Hillen W (1998). A novel protein kinase that controls carbon catabolite repression in bacteria. *Mol Microbiol*. 27: 1157-1169. (\*equal contribution). Impact Factor: 2.85

78. Kunst F, Ogasawara N, Moszer I, Albertini AM, ... **Rivolta C**, ... *et al.* (1997). The complete genome sequence of the gram-positive bacterium *Bacillus subtilis*. *Nature*. 390: 249-256. Impact Factor: 38.59

## Reviews

1. Royer-Bertrand B and **Rivolta C (2015)**. Whole genome sequencing as a means to assess pathogenic mutations in medical genetics and cancer. *Cell Mol Life Sci* 72:1463-71
2. Azzedine H, Senderek J, **Rivolta C** and Chrast R (2012). Molecular genetics of Charcot-Marie-Tooth disease: from genes to genomes. *Mol Syndromol*. 3:204-14.
3. **Rivolta C**, Berson EL and Dryja TP (2001). Dominant Leber congenital amaurosis, cone-rod degeneration, and retinitis pigmentosa caused by mutant versions of the transcription factor CRX. *Hum Mutat*. 18: 488-498.

## Book chapters

1. Benaglio P and **Rivolta C** (2012). Strategies for genetic screening of multiple samples using PCR-based targeted sequence enrichment. In: "Genomics III – Methods, Techniques and Applications". iConcept Press.